Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.59 |
| ▸ | JAK2 | O60674 | 2/20 | 0.59 |
| ▸ | JAK1 | P23458 | 2/20 | 0.59 |
| ▸ | BRD2 | P25440 | 2/20 | 0.59 |
| ▸ | JAK3 | P52333 | 2/20 | 0.59 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.59 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 7/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.55 |
| ▸ | INSR | P06213 | 2/20 | 0.55 |
| ▸ | IGF1R | P08069 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26983507 | 0.93 | BRD4 (0.70) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL24256003 | 0.84 | EGFR (0.69) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL24255886 | 0.84 | BRD4 (0.77) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL20398846 | 0.79 | ALK (0.75) | BRD4JAK2EGFRALKINSR | |
| SCHEMBL24255337 | 0.78 | BRD4 (0.64) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL24255885 | 0.77 | BRD4 (0.80) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL24255895 | 0.77 | BRD4 (0.70) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL24255308 | 0.75 | EGFR (0.70) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL24255898 | 0.75 | EGFR (0.80) | BRD4EGFRALKINSRIGF1R | |
| SCHEMBL18757714 | 0.75 | BRD4 (1.00) | BRD4JAK2JAK1BRD2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022036313-A1 | PYRIMIDINYL SULFONAMIDES AS INHIBITORS OF ACK1/TNK1 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |